Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple myeloma patients. Cevostamab delivered feasible and well-tolerated ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Tamara Mobley's persistent back pain led to a multiple myeloma diagnosis after initial dismissive medical consultations. Her ...

Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...